Gastroesophageal Reflux Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Phantom Pharmaceuticals, Sinorda Biomed

The Gastroesophageal Reflux Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.
DelveInsight's "Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease Market Forecast [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Gastroesophageal Reflux Disease Market Report:

* The Gastroesophageal Reflux Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In March 2024, Implantica commenced the premarket approval process with the US Food and Drug Administration (FDA) for its RefluxStop treatment intended for gastroesophageal reflux disease (GERD). The Liechtenstein-based company aims to obtain approval for RefluxStop through the US FDA's premarket approval application (PMA) modular review program. This approach permits companies to complete sections, known as modules, at various intervals. Final confirmation is granted once all sections of the PMA are completed. Additionally, the program facilitates ongoing review and feedback from the FDA as modules are submitted.
* In May 2023, Phathom Pharmaceuticals refiled its New Drug Application with the FDA for vonoprazan, aiming to secure approval for treating erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.
* According to Marco G. Patti (2020), a significant portion of Americans, estimated at 25% to 40%, encounter symptomatic gastroesophageal reflux disease (GERD) at various times, with approximately 7% to 10% experiencing daily symptoms. While many manage their symptoms using over-the-counter (OTC) medications and without seeking medical advice, the actual GERD prevalence is likely higher.
* Key Gastroesophageal Reflux Disease Companies: Phantom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
* Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
* The Gastroesophageal Reflux Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

Gastroesophageal Reflux Disease Overview

Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder characterized by the reflux of stomach acid into the esophagus, causing irritation and inflammation. It occurs when the lower esophageal sphincter (LES), a ring of muscle between the esophagus and stomach, becomes weak or relaxes inappropriately, allowing stomach contents to flow back up into the esophagus.

Get a Free sample for the Gastroesophageal Reflux Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market [https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Reflux Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroesophageal Reflux Disease Epidemiology Segmentation:

The Gastroesophageal Reflux Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Gastroesophageal Reflux Disease
* Prevalent Cases of Gastroesophageal Reflux Disease by severity
* Gender-specific Prevalence of Gastroesophageal Reflux Disease
* Diagnosed Cases of Episodic and Chronic Gastroesophageal Reflux Disease

Download the report to understand which factors are driving Gastroesophageal Reflux Disease epidemiology trends @ Gastroesophageal Reflux Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to get launched during the study period. The analysis covers Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Reflux Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroesophageal Reflux Disease Therapies and Key Companies

* Vonoprazan: Phathom Pharmaceuticals
* X842: Sinorda Biomedicine
* BLI5100: Sebela Pharmaceutical
* Linaprazan glurate: Cinclus Pharma
* Naronapride: Renexxion Ireland
* Fexuprazan: Daewoong Pharmaceutical
* IN-C003: HK inno.N
* IN-C002: HK inno.N
* CKD-382: Chong Kun Dang Pharmaceutical
* IN-C004: HK inno.N
* AD-214: Addpharma
* JP-1366: Jeil Pharmaceuticals
* Naronapride: Renexxion
* Fexuprazan: Daewoong Pharmaceutical

Discover more about therapies set to grab major Gastroesophageal Reflux Disease market share @ Gastroesophageal Reflux Disease Treatment Landscape [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastroesophageal Reflux Disease Market Strengths

* Lifestyle changes, including dietary adjustments, weight management, and elevating the head of the bed, offer non-pharmacological approaches to managing GERD and reducing symptom severity.
* There is a growing awareness of GERD among both healthcare professionals and the general population. This increased awareness leads to earlier diagnosis and improved management.

Gastroesophageal Reflux Disease Market Opportunities

* Multidisciplinary teams involving gastroenterologists, dietitians, psychologists, and surgeons can work collaboratively to provide comprehensive care and support for GERD patients.
* Promising new drugs, such as naronapride, vonoprazan, and BLI5100 are being developed to address GERD and its complications, providing potential alternatives for patients who are unresponsive to current treatments.

Scope of the Gastroesophageal Reflux Disease Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Gastroesophageal Reflux Disease Companies: Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
* Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
* Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
* Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Gastroesophageal Reflux Disease Unmet Needs, KOL's views, Analyst's views, Gastroesophageal Reflux Disease Market Access and Reimbursement

To know more about Gastroesophageal Reflux Disease companies working in the treatment market, visit @ Gastroesophageal Reflux Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Gastroesophageal Reflux Disease Market Report Introduction

2. Executive Summary for Gastroesophageal Reflux Disease

3. SWOT analysis of Gastroesophageal Reflux Disease

4. Gastroesophageal Reflux Disease Patient Share (%) Overview at a Glance

5. Gastroesophageal Reflux Disease Market Overview at a Glance

6. Gastroesophageal Reflux Disease Disease Background and Overview

7. Gastroesophageal Reflux Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Reflux Disease

9. Gastroesophageal Reflux Disease Current Treatment and Medical Practices

10. Gastroesophageal Reflux Disease Unmet Needs

11. Gastroesophageal Reflux Disease Emerging Therapies

12. Gastroesophageal Reflux Disease Market Outlook

13. Country-Wise Gastroesophageal Reflux Disease Market Analysis (2019-2032)

14. Gastroesophageal Reflux Disease Market Access and Reimbursement of Therapies

15. Gastroesophageal Reflux Disease Market Drivers

16. Gastroesophageal Reflux Disease Market Barriers

17. Gastroesophageal Reflux Disease Appendix

18. Gastroesophageal Reflux Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastroesophageal-reflux-disease-market-and-epidemiology-2032-treatment-market-therapies-companies-fda-approvals-epidemiology-and-forecast-by-delveinsight-phantom-pharmaceuticals-sinorda-biomed]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.